Good day, ladies and gentlemen, and thank you for standing by. Welcome to the BrightSpring Health Services, Inc. Second Quarter 2025 Earnings Call. [Operator Instructions]. I would now like to hand the conference over to the first speaker today. You may begin.

Good morning. Thank you for participating in today's conference call. My name is David Deuchler with Investor Relations for BrightSpring. I'm joined on today's call by Jon Rousseau, Chief Executive Officer; and Jen Phipps, Chief Financial Officer. Earlier today, BrightSpring released financial results for the quarter ended June 30, 2025. A copy of the press release and presentation is available on the company's Investor Relations website. Please note that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to our future financial performance and industry and market conditions. Such forward-looking statements are not guarantees of future performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. We encourage you to review the information in today's press release and presentation as well as in our quarterly report on Form 10-Q that will be filed with the SEC, including the specific risk factors and uncertainties discussed in our Form 10-K and Form 10-Q. Such factors may be updated from time to time in our periodic filings with the SEC, and we do not undertake any duty to update any forward-looking statements, except as required by law. During the call, we will use non-GAAP financial measures when talking about the company's financial performance and financial condition. You can find additional information on these non-GAAP measures and reconciliations of our non-GAAP financial measures to their most directly comparable GAAP financial measures to the extent available without unreasonable effort in today's earnings press release and presentation, which again are available on our Investor Relations website. This webcast is being recorded and will be available for replay on our Investor Relations website. And with that, I will turn the call over to Jon Rousseau, Chief Executive Officer.

Good morning, everyone, and thank you for joining BrightSpring second quarter 2025 earnings call. I would like to begin by expressing my gratitude to all of our BrightSpring teammates across the country who work hard to provide high-quality and compassionate care to patients every day. They make a tremendous impact. Through the first half of the year, we have executed on our plans across the organization with a high level of focus and discipline, and we are pleased with the performance of our businesses. Second quarter results exceeded expectations and have us well positioned to continue to deliver on our goals for the balance of the year. We remain committed to disciplined growth across the company by executing in each of our markets, while leveraging our scale and best practices, making smart growth investments and continuing to provide the high quality of care to patients. Before discussing BrightSpring second quarter performance, I would like to remind you that the company's financial performance and 2025 guidance principally pertain to the continuing operations and do not include results from the Community Living business. At this time, we expect the Community Living divestiture transaction to close in the fourth quarter of this year, subject to regulatory approvals and typical closing conditions, and we continue to work with the FTC as they complete their second review of the transaction. For the second quarter, BrightSpring's revenue and adjusted EBITDA both grew approximately 30% versus last year's comparable quarter. Total company revenue of $3.1 billion represented 29% growth year-over-year, with Pharmacy Solutions revenue of $2.8 billion increasing 32% year-over-year and Provider Services revenue of $358 million increasing 11% year-over-year. Total company adjusted EBITDA of $143 million in the quarter also grew 29% compared to the same period last year, driven by strong volume and revenue results…

Thank you, Jon. Before I discuss our results for the second quarter of 2025, I'd like to remind you that in the first quarter of this year, we began to record the Community Living business in discontinued operations, as indicated in the press release and 10-Q, to adhere to accounting standards required on an interim basis. As such, all BrightSpring financial results and forecasts that I will discuss are related to continuing operations and exclude Community Living. Management believes the presentation of the non-GAAP financials from continuing operations is a useful reflection of our current business performance. In the second quarter of 2025, total company revenue was $3.1 billion, representing 29% growth from the prior year period. Pharmacy Solutions segment revenue in the quarter was $2.8 billion, achieving 32% year-over-year growth. Within the Pharmacy segment, Infusion and Specialty revenue was $2.2 billion, representing growth of 39% for prior year, and Home & Community Pharmacy revenue was $587 million, representing growth of 11% year-over-year. Recently, we have fielded a few questions about a Home & Community Pharmacy customer that filed for bankruptcy. We plan to continue to service them and will be paid as they undergo the bankruptcy reorganization. Our pharmacy and company results in Q2 reflect any impact from this situation, and we are fully reserved. There will be no go-forward charge, and we do not expect this to have any material impact to our ongoing business. In the Provider Services segment, we reported revenue of $358 million in the second quarter, which represented 11% growth compared to the prior year. Within the Provider Services segment, home healthcare reported $185 million in revenue, growing 17% versus last year. Rehab revenue was $73 million, growing 9% versus last year, and personal care revenue was $100 million, representing growth of 4% year-over-year.…

Thank you for your time today to go through BrightSpring's second quarter 2025 results. We will now open up the call for questions. Operator?

[Operator Instructions] Our first question will be coming from Whit Mayo of Leerink Partners.

Yes. Jon, maybe to just start with the infusion performance in the quarter. I think you've referenced some leadership changes in the past. And just any expectations for growth over the next few years and how you're positioning the business for growth within, I guess, specifically within the acute market?

Whit, thank you for the question. Yes, we were pleased with a lot of the developments in the Infusion business in the quarter. I would say, from a progress perspective and from an operations perspective, it's the best quarter we've had in a long time, and we expect more of the same. From a leadership perspective, we do have a new President of that business who started early in the quarter. We have a new operations leader. We have a new sales leader. So we have really focused on not only trying to make the business as efficient as possible to drive optimal patient outcomes and drug turnaround times, but also to do that, hopefully, with the best talent base that we have in the industry as well as ongoing technological and process investments. And so super excited about the business. The business grew a double digit on an EBITDA basis in the quarter, and we expect much more of the same in the future. It certainly is one of our drivers in the back half of the year. And I view it as one of our top, certainly, 2 or 3 growth drivers in the company in the future. In particular, we're really excited about acute. I've stated our strategy there before is to not abandon that market. I think like a lot of people have, it's a tough market, but it's also a very, very large market. And it's one that we are trying to make sure we have optimal customized processes, too. So we will certainly continue to address chronic therapies, but we think having a broad-based strategy that also includes acute and focuses on professional services and nursing services and optimal payer relationships by the broad set of services you do have is ultimately a winning strategy, not only across the home, but across clinics as well. So numerous growth levers in Infusion going forward, provide essential services that dramatically reduce costs versus doing these types of procedures in a hospital setting, and we just continue to focus on the team and the process there. Thank you.

Great. And maybe just the follow-up on just the gross profit per script was up a good bit. And just any comments around trying to square that performance to be helpful in the context of maybe what to expect for the rest of the year?

Yes. It was mix. I'll let Jen answer that a little bit more, but the trends we saw in Q2, we see continuing.

Yes. So as Jon mentioned in the script, there was 38% year-over-year growth in our Specialty scripts that has some of the highest gross profit in -- per script. And so we saw a skewing to that this quarter.

Our next question will be coming from A.J. Rice of UBS.

You beat at least relative to consensus by about $5 million in the second quarter and you're raising the full year guidance by $20 million. So clearly, there's some uplift in the back half numbers. I know you had assumptions about a lot of positives coming into the year, coming into this quarter. What specifically is improved resulting in that raise in the back half of the year that's different than coming into maybe the quarterly release?

Yes. A.J., thank you. We do always have slightly higher margins and EBITDA contribution in the back half of the year just due to structural items like the way Mondays and Fridays and the number of days in the month in the back half versus the first half as well as taxes that burn off into April and May throughout the year, that is part of it. I would say just continued momentum really across the company. Characterizing our performance was not just pharmacy, but continued real strength on the provider side. This is a business that continues to grow nicely into the double digits from an EBITDA perspective, and we've never been more positive about the Provider segment of our company as well. So really broad-based growth across the organization, but as we look at the back half, continued momentum, we do have expectations for continued growth across the company. We see Infusion continuing to grow more. We see home health and hospice from a volume perspective continuing to grow more in the second half. We do have quite a few efficiency, lean and technology initiatives that have been hitting in Q2 and Q3 that we also expect to continue to contribute in the back half. And then there's some favorable rate developments in the back half as well, including the hospice rule. Jen, I don't know if you had anything else.

Yes. I would just highlight, especially within our home infusion and long-term care pharmacy, we've had really focused efforts regarding those efficiency projects, additional procurement initiatives, those are coming online, as Jon mentioned. Again, really strong performance in Provider, continuing to leverage our scale and just seeing an accretion of margin related to those projects.

Okay. Great. And maybe my follow-up, just to drill down a little bit on the development in M&A. Usually, you do about $100 million in annual spend. Obviously, this year, you've got the Amedisys divestiture deal pending. Hopefully, that goes through. And you've got some priority on debt reduction, although most of that is coming from your home divestiture. Any updated thoughts on the pipeline or deals away from the Amedisys transaction that you might be looking at?

Yes. I would just say more of the same. I mean, we've certainly been a little bit measured here waiting for the outcome of the Community Living divestiture and what would happen on the Amedisys divestiture. So they're definitely and logically has been a wait-and-see approach, but more of the same in terms of our absolute baseline for M&A, which is 8 to 10-or-so tuck-ins a year at very, very low multiples. We are continuing to work on those. There -- you would see probably 5 to 10 of those on our current pipeline, tuck-ins, a lot of CON- type stuff at very low multiples, in some cases, just buying a license, that's really been our MO this year as we've been waiting to see what happens with the divestiture and then the Amedisys transaction. We are having a very strong cash year. Our OCF should be comfortably above $300 million, and we're pleased where we're heading with leverage. I think this gives us more flexibility into the future should we choose to be a little bit more aggressive anytime. But as we've been saying now for 20 months, our focus has been on driving the balance sheet to our target leverage level. Assuming the Community Living divestiture, again, we should be at or below 3x by the end of the year. And our long-term goal that we've stated as of more recently is 2x to 2.5x. We think we can be at that long-term goal of 2x to 2.5x leverage as soon as next year. And so we continue to be focused on that with a baseline level of very accretive small tuck-in M&A, as we await the outcomes of some of these other transactions.

Our next question will be coming from David Larsen of BTIG.

Congratulations on the good quarter. Jon, can you talk a little bit about the growth in the home health business? And I don't view the rule as being that material. I mean, it's less than 2% of total revenue, but I have been getting any questions on it. I think I heard you mentioned in your prepared comments that in 2017 (sic) [ 2027 ], there could be a 500 basis point lift because part of that proposed reduction is actually temporary. Just any color on growth and that rule.

Yes. You're right, David. We don't have a material impact from the outcome of the home health rule. Obviously, for the benefit of the industry and as an interested party, we do hope that the final rule better reflects the value that home health services provide. The ROI from home health is just simply unquestionable and profound, just reams and reams of data over the past 30 years, speaking to the benefit on mortality rates, on reduced hospitalizations and improve outcomes at lower costs. So hopefully, home health, just like many other and most other segments of health care services will get the support it deserves going forward. I think you meant 2027. If the recoupment does go into place, TBD based on the final rule, at some point, that will burn off and go away as well. And when it does, you'll have a big uplift, right? So -- and then we are optimistic, and based on some language that we saw in the proposed rule, that home health rates will start moving up again at some point in the near to medium-term future. Our approach to home health has been a steady but very measured growth into the space. Therefore, we are not a massive home health provider today. We're still a relatively modestly sized provider. Hospice is the predominance of what we do in home health and hospice today, but we have been growing into it over time. And we feel like that strategy and scaling into it over time will dovetail nicely with a return to warranted rate support in the home health industry. So we actually believe it's a very interesting time to be a provider who's growing into the space and creates a lot of opportunities into the future. But thank you, David, we would agree.

And our next question will be coming from Joanna Gajuk of Bank of America.

So maybe first question on the Specialty Pharmacy, right? Keeps, I guess, surprising to the upside, I'm not complaining. But just a question, how much longer can you grow at this pace? Would you refer to assume 30% growth in Specialty Pharmacy to continue next year?

Joanna, I think what we're seeing today is the benefits of a business in a business model, a value proposition and a track record from a service and quality perspective that's now been put in place for close to 15 years. If you look at our service levels and our quality, which is driving a lot of strong relationships with manufacturers in biopharma, if you look at the infrastructure investments we've made in the business, up and down the patient journey and the patient process, if you look at the investments we've made on the business development side of the organization, making sure that we can properly educate and advocate for these therapies with thousands of prescribers and patients and their families every day to make sure they get the life- saving therapies that they need, that's what we've done. And it's driving a solid amount of growth into the organization. It's a broad-based business, too. We really try to partner closely and be the best partner we can with the payers, with the PBMs and the manufacturers on the brand LDD side. We also try to make sure that we drive generic utilization when the opportunity arises. We have a growing and a thriving fee-for-service and hub business as well. And so growth is really coming from all dimensions of that business. And we're serving markets in the specialty pharmacy industry that are massive, that continue to have huge innovation pipeline. So as we sit here today, we do not see anything that changes that growth trajectory. We will continue to make the investments in the business and try to execute at the high levels that we are every single day.

And if I may, staying on pharmacy. The recent proposal for Medicare for outpatient hospitals includes provision right to equalize rates for some of the drugs provided by doctors at the hospitals to get paid on the fee schedule. So I don't know, is there some opportunity for you guys from changes like that? Would you be willing to comment on that?

Yes. Joanna, at this time, we're not really sure if that would be an additional opportunity or not. I mean, we are serving the Specialty Pharmacy segment of the market, principally, which is outside of the hospital, outside of the physician office. So that would be something that we'd have to further evaluate into the future. But thank you.

And our next question comes from Brian Tanquilut of Jefferies.

Congrats on the quarter. Jon, as I think about LDDs, maybe tying back to Joanna's question, right, I mean, you did 5 introductions in Q2, it sounds like. And so thinking about just the pace and the remaining pipeline for LDD intros, I don't know, you talked about new agreements. So just curious what you can share with us in terms of what that pipeline looks like and the runway.

Brian, look, the biotech companies and manufacturers are doing a terrific job of driving that innovation pipeline, continuing to bring more and more therapies to market. It's as deep as ever. A lot of them are more and more specialized, and I would say more and more niche from a patient population perspective. And that's an area that we have continued to try to be a terrific partner on. What we have continued to say is we expect 16 to 18 new brand LDD launches. Most of these are either exclusives or in ultra-narrow 1 of 2 pharmacy networks, 16 to 18 over the next 12 to 18 months. And we've been saying that really for the past 20 months, and that's what we're realizing as well. So we have a strong conviction that we will have another 16 to 20 LDDs, 16 to 18 months from now, and we're really honored that we could bring these ground breaking and life-changing therapies to patients as a partner with the innovators.

That makes sense. And then maybe, Jon, as I think about gene and rare disease in the Specialty Pharmacy business, I mean, how big of a business is that for you guys right now out of the book? I mean, I know everyone thinks oncology is the area of growth, but obviously, there are emerging areas in the drug world that could drive incremental growth and incremental dollars. So just curious what you can share with us on that front.

Yes. Thanks, Brian. I mean, that is a continually emerging area. Something people probably don't realize too well is, I mean, there is a solid percentage of our therapies that would be defined as rare and orphan therapies as well. Some of those are in oncology, some of those are not. But that is an area that we continue to look at. I would say if you look at our LDD wins in the last year, 30% to 40% of them have been in areas that would be defined as rare and orphan therapies as well. So we continue to lean in to that market internally. And it dovetails all of the critical success factors that have made -- that have allowed us to build the model that we have on the oncology side absolutely directly applied to rare and orphan. And I would say it does not go the other way. Being successful in rare and orphan does not necessarily make it easy to more -- enter the oncology space. For example, you look at our huge business development sales force investment that we could bring to bear, that you really don't see as a characteristic in other markets. And so we're constantly looking to see where we can leverage our core capabilities into adjacencies, and that's one that we have had a lot of success, and we will continue to. I mean, a good example is now going on about a year ago as we won the injectable for LEQEMBI, and we have to see how that plays out, but we weren't exclusive on that. So we are always looking to leverage terrific relationships with biopharma into more areas.

Our next question will be coming from Charles Rhyee of TD Cowen.

Jon, I wanted to drill down on some of your prepared comments. I know we -- a lot of people have asked about the LDDs. But obviously, when you look at some of the data from like IQVIA, we saw improving, also generics as well. Just maybe anything that you're seeing there? We saw generic unit penetration rates improving for oncology as well. Anything that you'd specifically call out in the quarter? And it seems like when you look at the script growth and the revenue growth as well, maybe it's mostly LDD launches, but just curious if how much generics might have had played a part in sort of the upside in the quarter.

Yes. Thanks, Charles. Look, in terms of our value proposition across pharmacy of driving better med adherence, which without that is 1 of the 2 leading causes of hospitalization and driving generic utilization, all of this drives outcomes and cost reduction in the value chain. We do focus on exactly that in the latter of generic utilization when there is the opportunity. I think one thing that's interesting to note is over the last 6, 7 years, we've continued to increase our investment into that clinical liaison team out in the field covering thousands and thousands of doctors' offices and oncology offices every day. And what that really does is makes us the de facto sales force for generic drugs, right? When a drug goes from brand to generic, a lot of the detailing goes away from the brand. And so -- but we have invested in a very large clinical liaison force that is out there every day with decades-long relationship with prescribers, and we were -- we are able to effectualize that conversion as rapidly as we can and to drive that market share. And so there is a business model that has been in place for a long time that we continue to try to refine, even further every year. But with some of the generic launches that occurred going back several years ago, one significant one in Q4, we've now had about 3 already in -- and this year, we've got several more, including POMALYST next year. We are just really trying to do our part to drive utilization and pull through when those events happen.

Yes. Appreciate that. Just maybe as a follow-up. Obviously, the other day, the President announced or apparently wrote some letters to pharma to kind of revive sort of the discussion around most-favored-nation pricing. Obviously, that's really aimed at the drug industry, but I know that folks have thought through maybe potential indirect effects that it might have downstream. Just curious, as you may be evaluated in the past, whether that's the executive order that was signed back in May or just thinking through potential unintended consequences of some of these measures. Maybe you can kind of opine on sort of your thoughts on how this might affect BrightSpring or -- and/or just pharmacy -- the pharmacy world in general?

Sure, sure. Well, look, I mean I would say at the outset, it's very difficult for us to comment on this topic as it is all extremely uncertain. We did not see yesterday as any new news. Clearly, there are ongoing negotiation between the administration and the pharmacy industry. Yesterday's letter was just the latest, albeit, public position, which has been very similar to the executive order previously a couple of months ago. I think the biopharma industry has made many public commitments as part of this negotiation process. We certainly don't have insight into it. I think it would be reasonable to assume that these discussions are going to continue. Again, we don't believe just given our strong value proposition in terms of what the pharmacies do to drive outcomes and cost reduction and generic utilization. We do not believe that the pharmacies or other providers of critical services to patients are an intended target of any of these negotiations. And any outcomes from the government and industry that are being discussed are really likely probably to play out, if any, over a very, very long period of time. So I mean, I guess, the only other sort of comment here is IRA is already going to be in effect, and IRA really gets that a lot or most of what this is about. And we've already sort of bracketed in a downside what we think that impact could be, which is extremely manageable. And we are continuing to work with policymakers to try to make sure that the pharmacies are not impacted by that, and that work is ongoing. From a Medicaid perspective, Medicaid drug rates are already extremely low. And states and patients do realize other cost reduction vehicles and access programs today. I would say, as…

Our next question will be coming from Erin Wright of Morgan Stanley.

So in terms of underlying market share gains and competitors getting out of the market, we've known about that for some time. It's been going on for some time, whether it's Quorum or otherwise. But how do you think about that as a driver going forward? Maybe in going to what you were just saying in terms of like M&A opportunities on the back of any sort of regulatory type of disruption, too, across the market, could that bring opportunities for you? And yes, how do you think about kind of organic opportunities as well as we think about others kind of getting out of the market and how long of a tail you have there?

Yes. Erin, certainly, you looked at some of the things that happened on the acute side of the market in infusion in the last couple of years, those have been opportunities for us and others in the market. As I said before, we do believe that the acute market in infusion is an attractive one. I don't know exactly, but it is some $8 billion to $10 billion sort of market size, which creates tremendous opportunity if you can move your market share, say, from 10%, 15% to 30% to 35%. And that's something that we are really focused on. As it relates more broadly to other providers, that is something that we are regularly looking to do. If you look at our M&A track record, our average pro forma multiple over a long period of time is about 4x. And so we really do focus on opportunistic situations where we can bring the best practices and the synergies of our scale platform to bear. I think the statistic now is that we're something like 66 out of 68 on acquisitions where what we have acquired is higher on EBITDA than when we bought it. And so I mean, it is literally almost an unblemished track record of being able to do acquisitions and grow them post close. So our base case for the industry on the pharmacy side is really no significant disruption, but I think our platform positions us extremely well. As I've said before, we just really believe in health care moving forward that you do have to be a scale provider that can drive more sophisticated care, innovation, leveraging technology and driving efficiencies. It's just a necessity, and it's beneficial in so many different ways. And I think we continue to realize the benefits of that.

And one quick one just on your mix on the Specialty Pharmacy side. Have you given -- and maybe I've missed it in my notes or in your remarks in the past, but have you given a generic penetration rate?

I do not believe that we have. I would say that we have continued to say that as a pharmacy, a key part of our value proposition is driving generic utilization. We're very proud of that. Generics are good for everybody, and that is the majority of our business on the pharmacy side across our platforms.

And our next question will be coming from Matthew Gillmor of KeyBanc.

I wanted to see if you could provide some details on the procurement efforts that you've mentioned. I appreciate it's probably a normal part of managing the business. Is there anything in particular happening this year that makes procurement more of an opportunity maybe in terms of your scale or in terms of just contracts that are up?

Yes. I would say when we refer to "procurement," it goes across literally almost everything we're buying in this company. It's not just delivery. It's not just drug. It's not just supplies. We have a very robustly sized procurement team. We use ongoing monitoring and tracking with our data systems and technology to literally constantly be looking at everything we are buying and leveraging our scale as much as we can. So it's a team that is working on 20 to 30 projects at all times. And it really spans across every dimension of what we buy in the company, and it continues to drive savings every year. I think that will just continue more into the future. Obviously, if you look at our company, we start with the biggest spend in the company. You can probably think about what that is. And then we go down from there, and we work on all of it. And we try to do that in a very constructive way with our partners. And as we have continued to scale the company in very high volume rates, that has continued to benefit us on the cost side and driving more and more efficiencies. But it really goes beyond just trying to buy better. We are looking at continuous improvement that is embedded in our culture across all of our processes and something that we were close to saying in our prepared remarks, but we did not. I think in the next quarter or 2, we might say a little bit more about it. But we really continue to lean into technology and automation and now AI at the company as well. We've continued to make a lot of really terrific hires in the organization through the year. While we're experiencing this growth and continued growth, we want to continue to invest for years out and plant more and more seeds for growth 3 to 5 years from now. And part of that is reflected in the amount of key hires that we just continue to make from the outside in terms of A+ people through and through the organization. We've done that in Infusion. We've done that in Home & Community Pharmacy, and we're doing that in our IT shop as well. I mean, you look at our EMRs, intake, rev cycle, scheduling, operations, patient management, in every one of those areas, we have ongoing automation and AI initiatives right now. And we're really excited about that. We look at something like Home & Community Pharmacy, and we see a couple of hundred million dollars of cost opportunities still ahead of us in the next 3 years. Now we have to go execute against that, but those are the types of things that we are working on every single day here.

And our next question will be coming from Larry Solow of CJS Securities.

Great. I guess, just first question, anything -- any update on just bundling the services and your value-based contract efforts with ACOs that you can provide?

Larry, yes, I would say that business continues to progress along. We are going to see nice performance year-over-year in that business this year. That is a solidly profitable business between our ACO shared savings that we will realize and our little but growing I-SNP plan in the future. So progressing, directionally positive, positive year-over-year. We are making more and more investments in that business to try to scale that even faster. We've got some new people on that business here in the last 3 to 6 months. I think that's one that really getting into next year and 2027, I think we can start to really talk more about and potentially start to break out some numbers on in terms of it being a more material EBITDA contributor. But that's an area that continues to get a lot of internal attention. It's a slower build, but it's one that we continue to focus on.

And you had thrown out like a $100 million potential target in 5 years for EBITDA. Is that still something that you're comfortable with?

That is still our internal goal, yes.

Great. And then just secondly, just a quick follow-up, just on your build-out -- your hospice efforts build-out. Just a quick question just on Haven Hospice. I think it's about a year now since you bought that one. How is that progressing?

Haven would be a really good example of our M&A prowess and what we're able to do. I mean, that was a business that was essentially losing money a year ago. And now it is performing extremely well, well ahead of expectations. We will probably work ourselves into a 4x multiple there, I would say, run rate probably within the next 6 months. Team has just done an absolutely terrific job.

And I would now like to turn the call back to Jon for closing remarks.

Thank you for joining us, everybody, today. We really appreciate it. Thank you for all the questions, and we hope you have a great day. We look forward to talking with you again after Q3, and we really appreciate your time and attention. Have a good one. Bye.

This concludes today's conference call. Thank you for participating. You may now disconnect.